ArticleJournal of cancer research and clinical oncology2022
Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?
Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 5 citations in OpenAlex.
- Over- and underscreening for lung cancer.Translational lung cancer research · 2026Review
- CT-based interpretable delta-radiomics model for risk stratification of pulmonary ground-glass nodules: a multicentre study.Insights into imaging · 2026Article
- LDCT screening for lung cancer in East Asian never-smokers: balancing benefits and overdiagnosis-related harms.The Lancet regional health. Western Pacific · 2026Review
- Bridging the lung cancer screening eligibility gap: evaluation of guideline applicability in asymptomatic patients.Military Medical Research · 2026Observational
- Assessing Invasiveness of Ground-Glass Nodules Using Ternary-Class CT Radiomics Models: A Multi-Center Study with SHAP Explanations.Cancer management and research · 2026Article
- Deep learning and radiomics fusion for predicting the invasiveness of lung adenocarcinoma within ground glass nodules.Scientific reports · 2025Article
- Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution.Frontiers in oncology · 2023Article
- Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThis study investigates whether lead-time bias contributes to the excellent survival of AIS and MIA.
methodsWe enrolled patients with resected adenocarcinoma from 2008 to 2012. Age, sex, smoke history, surgical approach, radiological features, invasive stage and postoperative follow-up data were documented. 1:1 PSM was performed to balance the influence of sex and smoking status on survival. After matching, the average age of the two groups was compared to calculate the lead time of diagnosis. The gain in life years for adenocarcinoma diagnosed at pre-/minimally invasive stage was estimated by subtracting the "lead time" and "median survival year of IAC" from "the life expectancy of AIS/MIA patients" referring to the Centre for Health and Information.
resultsThere were 124 AIS/MIA patients and 1148 IAC patients. The frequency of female and never-smoking patients in AIS/MIA group was much higher than that in IAC group. PSM analysis identified 124 patient pairs. No cancer-related death and recurrence were observed among AIS/MIA patients 5 years after surgery. For IAC patients, the 5-year disease-specific survival rate was 73.5% and the median survival is 13.5 years. The average age of AIS/MIA group and IAC group are 53.6 years and 58.2 years, respectively. The lead time between diagnosis of AIS/MIA and IAC is 4.6 years. Referring to the Centre for Health and Information, the life expectancy of patients with AIS/MIA diagnosed at 53.6 years old is 28.9 years. With adjustment for the lead time, the gain in life years for adenocarcinoma diagnosed at pre-/minimally invasive stage is 10.8 years.
conclusionsWith adjustment for the lead time between diagnosis of AIS/MIA and IAC, resecting lung adenocarcinoma at pre-/minimally invasive stage can improve life expectancy. The excellent survival of AIS/MIA is not lead-time bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.